. 2017 May 4;8(27):43653–43661. doi: 10.18632/oncotarget.17613

Table 2. Progression-free survival, overall survival, time to discontinuation of treatment, and time to first and second subsequent therapy for somatic- and germline-BRCA1/2-mutated patients with platinum-sensitive high-grade serous ovarian cancer receiving olaparib 400 mg twice daily or placebo in Study 19 (data cut-off November 26, 2012).

Cohort	Endpoint	Treatment	N	Number of events (%)	HR	95% CI
Somatic BRCA	PFS^a	Olaparib	10	3 (30)	0.23	0.04, 1.12
	PFS^a	Placebo	10	8 (80)	0.23	0.04, 1.12
	OS	Olaparib	10	3 (30)	0.15	0.02, 0.88
	OS	Placebo	10	7 (70)	0.15	0.02, 0.88
	TDT	Olaparib	10	7 (70)	0.23	0.05, 0.93
	TDT	Placebo	10	10 (100)	0.23	0.05, 0.93
	TFST	Olaparib	10	6 (60)	0.48	0.12, 1.91
	TFST	Placebo	10	8 (80)	0.48	0.12, 1.91
	TSST	Olaparib	10	5 (50)	0.39	0.08, 1.63
	TSST	Placebo	10	8 (80)	0.39	0.08, 1.63
Germline BRCA	PFS^a	Olaparib	49	16 (32.7)	0.17	0.09, 0.34
	PFS^a	Placebo	44	30 (68.2)	0.17	0.09, 0.34
	OS	Olaparib	49	24 (49.0)	0.62	0.34, 1.12
	OS	Placebo	44	22 (50.0)	0.62	0.34, 1.12
	TDT	Olaparib	49	39 (79.6)	0.37	0.23, 0.59
	TDT	Placebo	44	41 (93.2)	0.37	0.23, 0.59
	TFST	Olaparib	49	30 (61.2)	0.33	0.20, 0.54
	TFST	Placebo	44	38 (86.4)	0.33	0.20, 0.54
	TSST	Olaparib	49	27 (55.1)	0.39	0.23, 0.66
	TSST	Placebo	44	33 (75.0)	0.39	0.23, 0.66

^aData cut-off June 30, 2010. N, number of patients with a mutation